Ryan M. Reyes
0000-0002-9562-5809
Publication & Citation Trends
Publications
0 total
Anti-PD-L2 immunotherapy is efficacious against melanoma in aged hosts through IL-17 and IFNγ signalling
Cited by 2
Semantic Scholar
Tumour-intrinsic PDL1 signals regulate the Chk2 DNA damage response in cancer cells and mediate resistance to Chk1 inhibitors OA
Cited by 8
Semantic Scholar
Pharmacological tumor PDL1 depletion with chlorambucil treats ovarian cancer and melanoma: improves antitumor immunity and renders anti-PDL1-resistant tumors anti-PDL1-sensitive through NK cell effects OA
Cited by 10
Semantic Scholar
Immune checkpoint expression and relationships to anti-PD-L1 immune checkpoint blockade cancer immunotherapy efficacy in aged versus young mice OA
Cited by 23
Semantic Scholar
DISTINCT EFFICACY AND IMMUNOLOGICAL RESPONSES TO a PD-1, Α PD-L1 AND Α PD-L2 IMMUNOTHERAPY IN AGED VERSUS YOUNG HOSTS
Cited by 1
Semantic Scholar
CD122-SELECTIVE IL-2 COMPLEXES TREAT OVARIAN CARCINOMAS, INDUCE TREG FRAGILITY AND PROMOTE T CELL STEM CELLS
Cited by 1
Semantic Scholar
Bladder cancer cell‐intrinsic PD‐L1 signals promote mTOR and autophagy activation that can be inhibited to improve cytotoxic chemotherapy OA
Cited by 42
Semantic Scholar
Intracellular PD-L1 regulates DNA damage checkpoints and suppresses Chk1 and PARP inhibitor synthetic lethality
Cited by 0
Semantic Scholar
Research Topics
Cancer Immunotherapy and Biomarkers
(39)
Bladder and Urothelial Cancer Treatments
(27)
Immune Cell Function and Interaction
(22)
Immunotherapy and Immune Responses
(16)
Epigenetics and DNA Methylation
(10)
Affiliations
The Graduate Center, CUNY
The University of Texas MD Anderson Cancer Center
The University of Texas Health Science Center at San Antonio
California State University Los Angeles
Audie L. Murphy Memorial VA Hospital